PETNET Solutions entered into an exclusive agreement with Zionexa to manufacture and distribute Zionexa's PET radiopharmaceutical fluoroestradiol. The FDA has yet to approve fluoroestradiol, which is approved in France for estrogen receptor status characterization in patients with metastatic breast cancer.
PETNET Solutions to manufacture, distribute Zionexa's PET radiotracer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.